For research use only. Not for use in humans.

Fresolimumab (Anti-TGFb1)

Synonyms: TGF-beta-1， TGFB1 Cat.No.A2336 Purity:99%

Fresolimumab (Anti-TGFb1) is a pan-specific, recombinant, fully human monoclonal antibody directed against human transforming growth factor (TGF) beta 1, 2, and 3 with potential antineoplastic activity. MW : 145.5 KD.

Quality Control

Batch: A233601 Purity: 99% Protein concentration: 3.06 mg/ml Endotoxin Level: ＜1EU/mg

Cited in Nature Medicine for its top-tier quality
COA
SDS
Datasheet

Featured Inhibitors	Y-27632 Dihydrochloride SB431542 CHIR-99021 (Laduviglusib) RMC-7977 RMC-6236 (Daraxonrasib) MRTX1133 MG132 Z-VAD-FMK VT3989 IAG933

Specificity

Name	Citation	ALK1	ALK2	ALK3	ALK4	TGFβRI/ALK5	ALK6	TGFβRII	TGF-β	Smad3	ALK7	Others
SB431542	826					+
LDN-193189	278	++++	++++	+++			+++
Galunisertib (LY2157299)	193					+
LY2109761	138					++		+
SB-525334	120					+++
SB505124	37				+	++
GW788388	26					++
LY364947	49					+		+				RIPK2,CK1δ,MLK-7K
RepSox (E-616452)	86					+++
LDN-193189 Dihydrochloride	108	++++	++++	+++			+++
K02288	25	++++	++++	++			+++
TGFβRI-IN-3	2					++++
R-268712	1					++++
BIBF-0775	0					++
TP0427736 HCl	6					+++
A-83-01	75				++	+++					+++
LDN-214117	4		++
SD-208	23					++
Vactosertib (TEW-7197)	29				+++	+++
ML347	5	++	++
LDN-212854	8	++++	++++	+	+	+
DMH1	63		+
Dorsomorphin Dihydrochloride	515		✔									AMPK
PF-06952229	0					✔
Ginsenoside Rh4	0								✔
SIS3	17									✔
AUDA	1								✔			TNF-α,IL-1β,MMP-9
PD 169316	2								✔			Activin A,Enterovirus71,p38 MAPK
TA-02	0							✔				p38 MAPK
ITD-1	15								✔
LY 3200882	7					✔
Alantolactone	3									✔		STAT3
Halofuginone	13									✔		prolyl-tRNA synthetase
SIS3 Hydrochloride	86									✔
Dorsomorphin (Compound C)	478		✔									AMPK
Hesperetin	4								✔			Histamine receptor

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description	Fresolimumab (Anti-TGFb1) is a pan-specific, recombinant, fully human monoclonal antibody directed against human transforming growth factor (TGF) beta 1, 2, and 3 with potential antineoplastic activity. MW : 145.5 KD.

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

CAS No.	948564-73-6
Molecular Weight	145.5 kDa
Isotype	Human IgG4SP
Source	CHO
Purification	AKTA
Sterility	0.2 μM filtered
Formulation	100 mM Pro-Ac, 20mM Arg, pH5.0
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02581787	COMPLETED		Stage IA Non-Small Cell Lung Carcinoma; Stage IB Non-Small Cell Lung Carcinoma	Maximilian Diehn	2016-08	PHASE1; PHASE2
NCT03064074	COMPLETED	Drug: Fresolimumab	Osteogenesis Imperfecta	Baylor College of Medicine	2017-11-15	PHASE1
NCT01401062	COMPLETED	Drug: Fresolimumab	Metastatic Breast Cancer	Weill Medical College of Cornell University	2011-07	PHASE2
NCT01665391	COMPLETED	Drug: fresolimumab\|Drug: fresolimumab\|Drug: Placebo	Primary Focal Segmental Glomerulosclerosis	Genzyme, a Sanofi Company	2012-08	PHASE2
NCT01284322	COMPLETED	Drug: Fresolimumab	Diffuse Systemic Sclerosis	Boston University	2011-01	PHASE1

(data from https://clinicaltrials.gov, updated on 2024-03-27)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.